NCT02626065View on ClinicalTrials.gov

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 23, 2015

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

blood sampling

Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)

DRUG

Nivolumab

injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.

Trial Locations (1)

69310

Centre Hospitalier Lyon Sud, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02626065 - Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies | Biotech Hunter | Biotech Hunter